A novel positive modulator of α4-GABAA receptors, XHe-III-74, reduces ethanol intake in mouse „drinking in the dark“ model

Author(s):  
Bojan Batinic
NeuroRx ◽  
2006 ◽  
Vol 3 (3) ◽  
pp. 413-414
Author(s):  
R KAMINSKI ◽  
H MARINI ◽  
P ORTINSKI ◽  
W YONEKAWA ◽  
S VICINI ◽  
...  

2020 ◽  
Vol 15 ◽  
pp. 263310552097541
Author(s):  
Kolter B Grigsby ◽  
Antonia M Savarese ◽  
Pamela Metten ◽  
Barbara J Mason ◽  
Yuri A Blednov ◽  
...  

High Drinking in the Dark (HDID-1) mice represent a unique genetic risk model of binge-like drinking and a novel means of screening potential pharmacotherapies to treat alcohol use disorders (AUDs). We tested the effects of tacrolimus (0, 0.5, 1, and 2 mg/kg), sirolimus (0, 5, 10, and 20 mg/kg), palmitoylethanolamide (PEA; 0, 75, 150, and 225 mg/kg), and secukinumab (0, 5, 20, and 60 mg/kg) on binge-like ethanol intake (2-day, “Drinking in the Dark” [DID]) and blood alcohol levels (BALs) in HDID-1 mice. Tacrolimus reduced ethanol intake and BALs. Tacrolimus had no effect on water intake, but reduced saccharin intake. There was no effect of sirolimus, PEA, or secukinumab on ethanol intake or BALs. These results compare and contrast with previous work addressing these compounds or their targeted mechanisms of action on ethanol drinking, highlighting the importance of screening a wide range of models and genotypes to inform the role of neuroimmune signaling in AUDs.


2005 ◽  
Vol 29 (9) ◽  
pp. 1630-1640 ◽  
Author(s):  
Matthew M. Ford ◽  
Jeffrey D. Nickel ◽  
Tamara J. Phillips ◽  
Deborah A. Finn

2005 ◽  
Vol 516 (3) ◽  
pp. 204-211 ◽  
Author(s):  
Maria Paola Mascia ◽  
Battistina Asproni ◽  
Fabio Busonero ◽  
Giuseppe Talani ◽  
Elisabetta Maciocco ◽  
...  

2005 ◽  
Vol 16 (Supplement 1) ◽  
pp. S36-S37
Author(s):  
R.J. Rodgers ◽  
C.N. Johnson ◽  
C. Ruckledge

2019 ◽  
Vol 9 (7) ◽  
pp. 171 ◽  
Author(s):  
Stacey L. Robinson ◽  
Carlos A. Perez-Heydrich ◽  
Todd E. Thiele

Corticotropin releasing factor (CRF) signaling via limbic CRF1 and 2 receptors (CRF1R and CRF2R, respectively) is known to modulate binge-like ethanol consumption in rodents. Though CRF signaling in the medial prefrontal cortex (mPFC) has been shown to modulate anxiety-like behavior and ethanol seeking, its role in binge ethanol intake is unknown. Here, we used “drinking-in-the-dark” (DID) procedures in male and female C57BL/6J mice to address this gap in the literature. First, the role of CRF1R and CRF2R signaling in the mPFC on ethanol consumption was evaluated through site-directed pharmacology. Next, we evaluated if CRF1R antagonist reduction of binge-intake was modulated in part through CRF2R activation by co-administration of a CRF1R and CRF2R antagonist. Intra-mPFC inhibition of CRF1R and activation of CRF2R resulted in decreased binge-like ethanol intake. Further, the inhibitory effect of the CRF1R antagonist was attenuated by co-administration of a CRF2R antagonist. We provide novel evidence that (1) inhibition of CRF1R or activation of CRF2R in the mPFC reduces binge-like ethanol intake; and (2) the effect of CRF1R antagonism may be mediated via enhanced CRF2R activation. These observations provide the first direct behavioral pharmacological evidence that CRF receptor activity in the mPFC modulates binge-like ethanol consumption.


2016 ◽  
Vol 791 ◽  
pp. 433-443 ◽  
Author(s):  
Tamara Timić Stamenić ◽  
Michael M. Poe ◽  
Sabah Rehman ◽  
Anja Santrač ◽  
Branka Divović ◽  
...  

2006 ◽  
Vol 317 (2) ◽  
pp. 694-703 ◽  
Author(s):  
Rafal M. Kaminski ◽  
Herbert Marini ◽  
Pavel I. Ortinski ◽  
Stefano Vicini ◽  
Michael A. Rogawski

Sign in / Sign up

Export Citation Format

Share Document